Skip to search formSkip to main contentSkip to account menu

AZD8330

Known as: ARRY-424704, ARRY-704, MEK Inhibitor AZD8330 
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Purpose B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively… 
2018
2018
In human lung cancer, Tripartite motif 65 (TRIM65) is documented as an important regulator in carcinogenesis. Knockdown of TRIM65… 
2017
2017
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… 
2015
2015
Conventional high-grade osteosarcoma is the most common primary bone cancer with relatively high incidence in young people… 
2015
2015
OBJECTIVE To investigate the effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its… 
Review
2014
2014
2014
This study was aimed to investigate the effect of MEK inhibitor AZD8330 on proliferation and apoptosis of multiple myeloma IM9… 
Review
2013
Review
2013
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… 
2009
2009
The dual-specificity kinases MEK 1/2 play key roles in tumorgenesis by activating the serine/threonine kinases ERK 1/2. These…